New drug combo aims to stop silent kidney transplant failure before it starts
NCT ID NCT06291103
Summary
This study is testing whether switching kidney transplant patients from standard anti-rejection drugs to a newer drug called belatacept can better control early, silent rejection. Researchers will enroll 290 adult kidney transplant recipients who develop certain antibodies but show no symptoms of rejection yet. The goal is to treat rejection earlier to prevent long-term kidney damage and transplant failure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.